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Abstract
A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither
inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100’s
of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the
ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and
research funders to make smarter investments in clinical research to save potential future costs.
Trial registration: NCT00405275, registered 29 November 2006
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Background
A recent randomized controlled trial in rheumatoid
arthritis (RA) patients determined that a strategy of first
adding two Disease-modifying Antirheumatic Drugs
(DMARDs) to methotrexate (a combination known as
Triple Therapy) is neither inferior nor less safe than first
adding the biologic anti-TNF drug etanercept to metho-
trexate in patients with active disease despite the metho-
trexate [1]. The Rheumatoid Arthritis Comparison of
Active Therapies (RACAT) trial, for which ethical ap-
proval was obtained from the institutional review boards
for each of the sites in the United States and Canada,
strengthens findings of earlier strategy trials that have
found triple therapy to be noninferior to biologic agents,
[2, 3] and a metaanalysis suggesting no difference in
their ability to prevent disease progression [4, 5].
The implication of the study, for which all 353 partici-
pants provided written informed consent, is that inex-
pensive triple therapy - a combination promoted for
over a decade but infrequently used - should be initiated
prior to commencing expensive biologic therapy in
patients whose disease is not completely controlled by
methotrexate alone. Furthermore, when patients fail a
regimen containing a biologic, they should switch to
Triple Therapy if it has not previously been tried instead
of presuming that a different biologic regimen is needed.
The results are particularly significant from a healthcare
cost and sustainability perspective since spending on
biologic therapies (which all appear to have near equal
efficacy [6]) for patients with RA ranks among the top
expenditure category in the formulary budgets of most
Western healthcare systems [7]. If implemented in prac-
tice, Triple Therapy would delay the use of biologic
treatment by at least 6 months without impairing a
patient’s disease progression, thereby saving $100’s of
millions each year.
It will, however, be a major challenge to change rheu-
matologists prescribing patterns given their familiarity
with biologics and guidelines advocating biologic use [8].
Arguably, the multimillion-dollar question raised by the
RACAT trial is why was it not conducted earlier? Both
biologics and Triple Therapy were independently shown
to be effective in comparison to methotrexate more than
15 years ago, [9, 10] but only recently have been com-
pared (Table 1).
Clinical trials are expensive to conduct, and more
trials are proposed than can be funded. Despite this, it
seems that priority is rarely given to trials where the
ultimate objective is to reduce future costs. While
“present and future resource implications” [11] are often
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considerations in funding research, it is rarely recog-
nized that there exists an opportunity cost associated
with each funding decision and that reducing costs has a
potential to significantly improve health, by releasing
money to be spent on alternative healthcare services that
provide greater health benefits. It seems the potential
opportunity for a blockbuster that industry recognizes
can make enormous profits is not reciprocated by payers
and research funders with the opportunity to save an
enormous amount of money.
With the benefit of hindsight, the $13 million spent on
the RACAT trial would have been recouped many times
over if conducted in the early 2000s. By looking back,
we consider the evidence and the uncertainties relating
to this trial in the early 2000s and reflect if we had the
foresight then to fund this trial. Most importantly, we
consider the lessons to determine which smart invest-




Timing is crucial in investing. By the time an investment
is obvious, much of the potential benefit is lost. In
the case of trials, they can only be funded if they have
been conceived with a plausible hypothesis and clear jus-
tification. However, the plausibility of Triple Therapy be-
ing equivalent to biologics was established by the early
2000s. A trial published in 1996 demonstrated that
Triple Therapy was superior in comparison to MTX
alone [7], and this was corroborated in 2002 [12]. While
numerous RCTs have been conducted on biologics in
Table 1 Clinical trials comparing biologics, Triple Therapy and methotrexate
Year Biologic vs. MTX Triple Therapy vs. MTX Triple Therapy vs. biologic
1996 TRI > MTX
1997
1998 INF > MTX
1999 INF > MTX, ETN >MTX TRI > MTX, TRI > MTX
2000 ETN >MTX, INF >MTX,
INF > MTX
2001
2002 ANA >MTX TRI > MTX
2003 ABA >MTX, ADA >MTX
2004 ANA >MTX, RIX > MTX,
ADA >MTX, ETN >MTX,
ETN >MTX, INF >MTX
2005 ABA >MTX, INF >MTX
2006 INF > MTX, ADA >MTX,
RIT > MTX, RIT > MTX,
ABA >MTX, TOC >MTX,
INF > MTX, INF >MTX
2007 INF > MTX, ADA >MTX,
ABA >MTX
2008 ADA >MTX, TOC >MTX,
ETN >MTX, GOL >MTX,
CER > MTX, INF > MTX,
TOC >MTX
2009 ADA >MTX, ADA >MTX,
GOL >MTX, TOC >MTX,
CER > MTX, ABA >MTX
2010 RIT > MTX, TOC >MTX,
ETN >MTX, GOL >MTX
2011 TOC >MTX
2012 CER > MTX, GOL >MTX TRI ≈ ETN, TRI ≈ INF
2013 ABA >MTX, ADA >MTX,
ADA >MTX, ETN >MTX,
TRI ≈ ETN
ABA, Abatacept; ADA, Adalimumab; ANA, Anakinra; CER, Certolizumab; ETN, Etanercept; GOL, Golimumab; INF, Infliximab; RIT, Rituximab; TOC, Tocilizumab;
TRI, Triple Therapy (methotrexate, sulfasalazine, hydroxychloroquine)
> indicates superiority in primary endpoint whereas ≈ indicates noninferiority
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RA over the past 15 years [6], regulatory approval has
meant nearly all have compared a biologic to placebo or
MTX in combination with placebo, with the vast ma-
jority in patients showing an inadequate response only
to MTX, not Triple Therapy. Table 1 describes how
more than 50 trials compared a biologic to MTX before
a comparison with Triple Therapy was made.
Estimated future market size
If biologics had not gone on to become expensive block-
buster drugs, the question of why the RACAT trial was
not conducted earlier would be moot. Nevertheless, this
could have been predicted; the prevalence of RA is ap-
proximately 1 % of the population, of whom it could be
predicted at least 10 % would be severe enough to be
marketable for biologic therapy. The price of biologics
was established with the first drugs of their kind - eta-
nercept and infliximab - and experience tells us that
these prices remain stable or indeed increase even when
new drugs enter the market. While the actual diffusion
of biologics into the market can be difficult to pre-
dict, if the pharmaceutical industry could anticipate
the potential market for biologics in the early 2000s
(numerous pre-clinical trials of other biologics were
in existence by 2002 [13]), then there is no reason re-
search funders could not also make these predictions.
Consideration of risk and reward
It is impossible to fund all trials with all plausible com-
parators, so the risk a trial will not meet its primary
endpoint has to be considered when deciding which
research to fund. Even in trials that meet their primary
endpoint, limitations exist in all studies, and these
limitations can impact whether the results influence
clinical practice. It is not clear how funders evaluate
these risks, or value what is an acceptable risk. However,
simple decision analysis can help discern the expected
value of information a trial would provide which can be
compared against the potential impact of the trial [14].
In the case of RACAT, the trial would have effectively
paid for itself in the first year in Canada alone, so it
would have been prudent to fund even if the risk of fail-
ure was very high.
Many payers have restricted access to biologics for
RA patients that have trialed specified conventional
DMARDs. For example, in Canada, reimbursement for
biologics by a government payer is only available
through a special authority where rheumatologists
usually must demonstrate that a number of DMARD
combinations have been previously tried. Including
Triple Therapy in this list would have been simple and
would have increased utilization substantially on the
basis of the evidence from a trial like RACAT to pro-
vide evidence.
Conclusions
Whether the RACAT trial will lead to reductions in the
use of biologics in patients with RA, and therefore pay-
ing for the investment remains to be seen. It is clear that
over 10 years ago, the RACAT trial would have been a
smart investment – we demonstrate that the anticipated
rewards would have indicated the risk was worth taking
many times over (Table 2). The result of the trial would
have had an influence on jurisdictions beyond the fund-
ing agency; however, the case for multinational studies
such as RACAT, where the costs are shared and the
Table 2 Proposed approach for making smarter investments
Stage Proposal Illustrative example of rheumatoid arthritis (RA) in
early 2000s in Canada
Identification (of the problem) Scan of pharmaceutical trials in phase 1, 2a/2b to
determine which products pharmaceutical
companies believe will be a good investment.
Numerous trials of biologic agents in RA from
multiple pharmaceuticals would have been
identified, suggesting a belief in the potential for
biologics to become blockbuster drugs.
Identification (of a potential solution) Call for studies of alternative, cheaper treatments in
clinical contexts identified above.
Triple therapy would have been proposed given
the O’Dell trial in 1996.
Estimated market size Consider the potential market size and assume the
price of first to market product to estimate the
potential budget impact.
A crude estimate of 0.1 % of the population using
the original price of the first biologics (~$18,000 per
year) would have led to a prediction of an
enormous potential market. In Canada, this would
be $500 million per year, or $5 billion, considering
10 years of use.
Consideration of risk and reward Estimate the cost of the trial – and compare with
the expected cost of a successful trial result
(probability of trial meeting the primary outcome
and subsequently impacting uptake multiplied by
the potential). If the cost of trial is greater, then do
not fund, but if it is less, then fund.
For a $10 million trial cost, it would only need to
have a minimum 0.2 % ($10 million < 0.2 x $5 billion)
chance of success for the trial to be deemed a good
investment in Canada. Given the evidence at the
time, even the most pessimistic assessment would
have provided a probability of success larger than
1 %. Hence, using this rationale, the trial would have
been funded.
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external validity is strengthened, are even more compel-
ling. With many new expensive treatments are emerging
for diseases such as asthma, hepatitis and cancer, among
others, a change in thinking about research investments
has the potential to save billions of dollars in the next
10 years.
An important issue to consider is who should pay for
these clinical trials? Regulatory bodies typically require ef-
ficacy studies instead of the comparative effectiveness
studies like RACAT, and there is little incentive for
pharmaceutical manufacturers to bear the cost. There is a
strong argument for regulatory studies to require com-
parative effectiveness studies, but they tend to be funded
through national health research budgets [15]. However, it
would have been the payers that would have ultimately
saved their budget through this trial. We believe payers
need to have a stronger voice in terms of both what regu-
lators require in terms of comparators from phase III
studies, and in terms of the way research funders invest in
evidence. If the healthcare system is serious about provid-
ing quality, cost-effective care, tremendous opportunities
remain through smart investments in clinical research.
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